BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...

XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...

XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016 BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and...

Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other...